Starpharma logo

Starpharma(ASX) SPL

Market CapA$405.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+8%
5 Year-27%
1 Year+217%
1 Month+21%
A$0.85
+0.59%
+0.01Today
Starpharma last closing stock price
MetricPriceDate
Last closeAUD 0.852026-10-12
Starpharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.94%AUD 0.812026-10-05
1 month+20.57%AUD 0.712026-09-11
3 month+15.56%AUD 0.742026-07-14
Year to date+142.36%AUD 0.352025-12-31
1 year+217.27%AUD 0.272025-10-10
3 year+523.21%AUD 0.142023-10-13
5 year-26.68%AUD 1.162021-10-13
Since inception+8.42%AUD 0.782000-09-28

Starpharma Financials at a Glance

Market Cap

A$405.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$17.90M

Net Income (TTM)

-A$17.46M

EPS (TTM)

-A$0.02

P/E Ratio

-48.84

Dividend

A$0.00

Beta (Volatility)

-0.04 (Low)

Price

A$0.85

Volume

2,594,664

Open

A$0.83

Previous Close

A$0.85

Daily Range

A$0.83 - A$0.86

52-Week Range

A$0.24 - A$0.88

Estimated Earnings Date

Mar 2, 2027

SPL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Starpharma

Starpharma Holdings Limited is a biopharmaceutical company dedicated to the research, development, and commercialization of dendrimer-based products across various industries, including pharmaceuticals and life sciences. The company is known for its innovative offerings, such as VivaGel, an effective treatment for bacterial vaginosis, and VIRALEZE, an antiviral nasal spray.

Products and Services
  • VivaGel: A non-antibiotic treatment for bacterial vaginosis
  • VIRALEZE: An antiviral nasal spray for respiratory infections
  • DEP technology: A platform for drug delivery in oncology and other applications
Growth Outlook
  • DEP docetaxel and DEP cabazitaxel are in Phase 2 clinical trials
  • Expansion into radiotheranostics for cancer diagnosis and therapy
  • Strong pipeline with multiple oncology candidates in development
Financial Highlights
  • Recent quarterly revenue of AUD 1.22 million, showing growth potential
  • Cash and cash equivalents of AUD 11.02 million as of June 2026
  • Current ratio of 3.40 indicates strong liquidity position
Starpharma Holdings Limited is positioned in the biotechnology sector, focusing on innovative solutions that address significant health challenges. The company's unique dendrimer technology has the potential to revolutionize drug delivery systems, particularly in oncology. With a robust pipeline of clinical candidates and a commitment to research and development, Starpharma is well-placed to capitalize on emerging opportunities in the biopharmaceutical landscape. The recent financial data reflects a solid liquidity position, which may support ongoing research initiatives and product development. Investors may find the company's strategic focus on innovative therapies appealing as it navigates the complexities of the healthcare market.
AI Generated • Sep 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

50

CEO

Cheryl Maley, MBA

Website

www.starpharma.com

Headquarters

Abbotsford, VIC 3067, AU

SPL Financials

Key Financial Metrics (TTM)

Gross Margin

86.26%

Operating Margin

-159.60%

Net Income Margin

-61.95%

Return on Equity

-42.35%

Return on Capital

-132.79%

Return on Assets

-39.25%

Earnings Yield

-2.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$405.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

479.74M

Volume

2.59M

Avg. Volume

2.37M

Financials (TTM)

Gross Profit

A$6.67M

Operating Income

-A$41.30M

EBITDA

-A$27.24M

Operating Cash Flow

-A$9.97M

Capital Expenditure

-A$329.00K

Free Cash Flow

-A$10.30M

Cash & ST Invst.

A$11.02M

Total Debt

A$707.00K

Starpharma Performance Analysis

Starpharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 2,939,000-37.2%
20242024-06-30AUD 8,289,000182.0%
20252025-06-30AUD 4,912,000-40.7%
20262026-06-30AUD 12,050,000145.3%
Starpharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3140.2%
Q42025-06-3041.0%
Q22025-12-31216.4%
Q42026-06-30-88.8%
Starpharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.04-3.9%
20242024-06-30AUD -0.02-48.1%
20252025-06-30AUD -0.0220.7%
20262026-06-30AUD -0.02-25.8%
Starpharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3124.9%
Q42025-06-3015.4%
Q22025-12-31130.0%
Q42026-06-30-718.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$1.22M

-29.6%

Gross Profit

A$355.00K

+110.2%

Gross Margin

29.15%

N/A

Market Cap

A$405.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$8.11M

N/A

Employees

50

N/A

Net Income

-A$8.83M

-23.9%

EBITDA

-A$14.79M

-143.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$11.02M

-52.8%

Total Debt

A$707.00K

-80.0%

Accounts Receivable

A$4.39M

-30.8%

Inventory

A$1.66M

-31.3%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$707.00K

-55.0%

Return on Assets

-39.25%

N/A

Return on Invested Capital

-1.39%

N/A

Free Cash Flow

-A$7.17M

+21.7%

Operating Cash Flow

-A$7.12M

+21.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,811.54+0.01%
^DJIDJI
$51,654.95+0.01%
^IXICNASDAQ
$27,366.17+0.01%
BTCBitcoin
$83,785.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$164.33+1.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$36.89+7.27%
NOKNokia
$10.05-3.03%
INTCIntel
$101.30-3.25%

Questions About SPL

What is the current price of Starpharma?

Starpharma is trading at A$0.85 per share.

What is the 52-week range for Starpharma?

Over the past 52 weeks, Starpharma has traded between A$0.24 and A$0.88.

How much debt does Starpharma have?

As of the most recent reporting period, Starpharma reported total debt of A$707.00K.

How much cash does Starpharma have on hand?

Starpharma reported A$11.02M in cash and cash equivalents in its most recent financial results.

What is Starpharma’s dividend yield?

Starpharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services